Literature DB >> 6360815

Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension.

P R Mills, A P Rae, D A Farah, R I Russell, A R Lorimer, D C Carter.   

Abstract

The effects of different types of adrenoreceptor blocking agents on portal venous pressure were studied in patients with cirrhosis and portal hypertension. Oral atenolol (selective beta 1 blocker), propranolol (non-selective beta 1 and beta 2 blocker), and prazosin (alpha blocker) were compared in three groups of eight patients. Haemodynamic measurements were made before and after two or three and eight weeks of therapy. The dose of beta blockers was sufficient to reduce the exercise heart rate by more than 25%. Propranolol and prazosin produced a sustained reduction in the mean portohepatic venous pressure gradient of the order of 25% and 18% respectively. The cardiac index was significantly reduced by propranolol but not altered by prazosin. Atenolol produced an early reduction in portohepatic venous pressure which, although not sustained, showed a good correlation with reduction in cardiac index. No such relationship was found with propranolol. All three drugs were well tolerated by these patients with advanced cirrhosis. Therefore propranolol and prazosin have proved to be effective agents for the reduction of portal venous pressure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6360815      PMCID: PMC1432238          DOI: 10.1136/gut.25.1.73

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  Circulatory changes in chronic liver disease.

Authors:  J F MURRAY; A M DAWSON; S SHERLOCK
Journal:  Am J Med       Date:  1958-03       Impact factor: 4.965

2.  Thermodilution cardiac output determination with a single flow-directed catheter.

Authors:  J S Forrester; W Ganz; G Diamond; T McHugh; D W Chonette; H J Swan
Journal:  Am Heart J       Date:  1972-03       Impact factor: 4.749

3.  Propranolol in decompensated alcoholic cirrhosis.

Authors:  J C Colman; G L Jennings; A J McLean; P R Mignot; F J Dudley
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

Review 4.  Intestinal blood flow.

Authors:  D N Granger; P D Richardson; P R Kvietys; N A Mortillaro
Journal:  Gastroenterology       Date:  1980-04       Impact factor: 22.682

5.  Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

Authors:  J McAinsh; N S Baber; R Smith; J Young
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

6.  Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis.

Authors:  P Hillon; D Lebrec; C Muńoz; M Jungers; G Goldfarb; J P Benhamou
Journal:  Hepatology       Date:  1982 Sep-Oct       Impact factor: 17.425

7.  Atenolol determination by high-performance liquid chromatography and fluorescence detection.

Authors:  Y G Yee; P Rubin; T F Blaschke
Journal:  J Chromatogr       Date:  1979-04-01

8.  Prazosin determination by high-pressure liquid chromatography using fluorescence detection.

Authors:  Y G Yee; P C Rubin; P Meffin
Journal:  J Chromatogr       Date:  1979-04-21

9.  Enhanced sympathetic nervous activity after intravenous propranolol in ischaemic heart disease: plasma noradrenaline splanchnic blood flow and mixed venous oxygen saturation at rest and during exercise.

Authors:  J F Hansen; B Hesse; N J Christensen
Journal:  Eur J Clin Invest       Date:  1978-02       Impact factor: 4.686

10.  Propranolol--a medical treatment for portal hypertension?

Authors:  D Lebrec; O Nouel; M Corbic; J P Benhamou
Journal:  Lancet       Date:  1980-07-26       Impact factor: 79.321

View more
  13 in total

Review 1.  Long term management of oesophageal varices.

Authors:  S K Sarin
Journal:  Drugs       Date:  1992       Impact factor: 9.546

2.  Computerised system for the continuous measurement of azygos venous blood flow.

Authors:  P C Hayes; D Terrace; I Peaston; I A Bouchier; D Redhead; H M Brash
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

Review 3.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

Review 4.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 5.  The medical prevention of variceal bleeding.

Authors:  D Lebrec
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

6.  Changes in blood flow, portal pressure and shunting during the development of cirrhosis in response to beta-blockade.

Authors:  M McLaren; S Braye; J Fleming; S Karran; I Taylor
Journal:  Gut       Date:  1987-06       Impact factor: 23.059

Review 7.  Cirrhotic cardiomyopathy: a cardiologist's perspective.

Authors:  Natig Gassanov; Evren Caglayan; Nasser Semmo; Gero Massenkeil; Fikret Er
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

8.  Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension.

Authors:  P Calès; D Grasset; A Ravaud; C Meskens; M Blanc; J P Vinel; J Cotonat; J P Pascal
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

Review 9.  Clinical pharmacology of portal hypertension.

Authors:  Cecilia Miñano; Guadalupe Garcia-Tsao
Journal:  Gastroenterol Clin North Am       Date:  2010-09       Impact factor: 3.806

10.  Prophylaxis of first variceal hemorrhage in patients with liver cirrhosis.

Authors:  T Sauerbruch; G Kleber; A Gerbes; G Paumgartner
Journal:  Klin Wochenschr       Date:  1986-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.